135 related articles for article (PubMed ID: 9274590)
1. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea.
Olivieri NF; Rees DC; Ginder GD; Thein SL; Brittenham GM; Waye JS; Weatherall DJ
Lancet; 1997 Aug; 350(9076):491-2. PubMed ID: 9274590
[No Abstract] [Full Text] [Related]
2. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
Dover GJ
Ann N Y Acad Sci; 1998 Jun; 850():80-6. PubMed ID: 9668530
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
Pearson HA
Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
[No Abstract] [Full Text] [Related]
4. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
5. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
Ajanta H; Chakraborty S; Madhusnata D; Bhattacharya DK; Manisha D
J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
[TBL] [Abstract][Full Text] [Related]
6. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
[No Abstract] [Full Text] [Related]
7. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
Ansari SH; Shamsi TS; Siddiqui FJ; Irfan M; Perveen K; Farzana T; Panjwani VK; Yousuf A; Mehboob T
J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
[TBL] [Abstract][Full Text] [Related]
8. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
Bhurani D; Kapoor J; Yadav N; Khushoo V; Agrawal N; Ahmed R; Arora JS; Mehta P
Ann Hematol; 2021 Jun; 100(6):1417-1427. PubMed ID: 33811502
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia.
Hoppe C; Vichinsky E; Lewis B; Foote D; Styles L
Am J Hematol; 1999 Dec; 62(4):221-7. PubMed ID: 10589077
[TBL] [Abstract][Full Text] [Related]
10. Use of hydroxyurea and recombinant erythropoietin in management of homozygous beta0 thalassemia.
Kohli-Kumar M; Marandi H; Keller MA; Guertin K; Hvizdala E
J Pediatr Hematol Oncol; 2002 Dec; 24(9):777-8. PubMed ID: 12468925
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Voskaridou E; Terpos E; Komninaka V; Eftyhiadis E; Mantzourani M; Loukopoulos D
Br J Haematol; 2002 Jan; 116(1):155-7. PubMed ID: 11841409
[TBL] [Abstract][Full Text] [Related]
12. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
Italia KY; Jijina FF; Chandrakala S; Nadkarni AH; Sawant P; Ghosh K; Colah RB
J Clin Pharmacol; 2010 Feb; 50(2):231-4. PubMed ID: 19797538
[No Abstract] [Full Text] [Related]
13. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome.
Singer ST; Kuypers FA; Olivieri NF; Weatherall DJ; Mignacca R; Coates TD; Davies S; Sweeters N; Vichinsky EP;
Br J Haematol; 2005 Nov; 131(3):378-88. PubMed ID: 16225658
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.
Karimi M; Zarei T; Bahmanimehr A; Aramesh A; Daryanoush S; Haghpanah S
Ann Hematol; 2021 Dec; 100(12):2901-2907. PubMed ID: 34383102
[TBL] [Abstract][Full Text] [Related]
15. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Banan M; Bayat H; Azarkeivan A; Mohammadparast S; Kamali K; Farashi S; Bayat N; Khani MH; Neishabury M; Najmabadi H
Hemoglobin; 2012; 36(4):371-80. PubMed ID: 22686296
[TBL] [Abstract][Full Text] [Related]
16. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
Italia KY; Jijina FF; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
[TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
Jain M; Chakrabarti P; Dolai TK; Ghosh P; Mandal PK; Baul SN; De R
Blood Cells Mol Dis; 2021 May; 88():102544. PubMed ID: 33610115
[TBL] [Abstract][Full Text] [Related]
18. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy Pattern.
Iqbal A; Ansari SH; Parveen S; Khan IA; Siddiqui AJ; Musharraf SG
Sci Rep; 2018 Oct; 8(1):15152. PubMed ID: 30310134
[TBL] [Abstract][Full Text] [Related]
20. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.
Singer ST; Kuypers FA; Olivieri NF; Weatherall DJ; Mignacca R; Coates TD; Davies S; Sweeters N; Vichinsky EP
Ann N Y Acad Sci; 2005; 1054():250-6. PubMed ID: 16339672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
